**Supplementary Table 1: Screening Criteria Used to Identify Relevant Articles for Review. FDA; Food and Drug Administration, CGRP; calcitonin gene related peptide, mAbs; monoclonal antibodies.**

|  |  |  |
| --- | --- | --- |
| **Study Parameter**  | **Inclusion Criteria**  | **Exclusion Criteria**  |
| **Study Treatment** | * FDA-approved CGRP-Targeting Therapeutic (as of February 2024)
* Gepants: Ubrogepant, Rimegepant, Atogepant, Zavegepant
* mAbs: Fremanezumab, Erenumab, Galcanezumab, Eptinezumab
 | * Non-FDA approved CGRP-targeting therapeutics.
* Non-CGRP-Targeting therapeutics
 |
| **Source of Funding**  | * Industry-sponsored
 | * Non-Industry sponsored
 |
| **Trial Design / Publication Type** | * Phase II or III Clinical Trial with efficacy outcomes
 | * Studies that did not assess efficacy (studies that only reported safety or tolerability outcomes)
* Extension-studies
* *Post-hoc* or secondary analysis of Phase II/III Clinical Trials
 |
| **Study Location**  | * Studies Conducted at sites in the United States
 | * Studies conducted at sites outside the United States
 |
| **Study Participants** | * Adult participants (18+)
 | * Pediatric participants (<18) or mixed adult/pediatric study participants
 |
|  **Publication Language**  | * English Publications
 | * Non-English Publications
 |